JPRN-UMIN000014140Completed未知
Efficacy and Safety of GLP-1 first therapy compared with Insulin GLP-1 relay therapy in type 2 diabetes with inadequate glucose control: a randomized, open-label, multicenter parallel-group study - Direct comparison of GLP-1 first therapy and Insulin-GLP-1 relay therapy.
Kanazawa university Department of Disease Control and Homeostasis0 sites120 target enrollmentStarted: June 2, 2014Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 120
Study Overview
Brief Summary
The GLP-1 receptor agonist is overall effective without prior glycemic control with insulin in participants with poorly controlled type 2 diabetes. However, in participants with insulinopenic type 2 diabetes, prior glycemic control with insulin may overcome glucose toxicity-induced GLP-1 resistance.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who have history of serious hypersensitivity to Liraglutide, Exenatide, Lixisenatide and insulin degludec. Patients with type 1 diabetes or impaired glucose tolerance due to other specific mechanisms or diseases or gestational diabetes. Patients with diabetic ketoacidosis Patients who have history of severe hypoglycemia with coma or loss of consciousness Patients with serious infection or severe traumatic injury Patients with steroids as unstable daily dose. Patients with unstable hypertension with medication like systolic blood pressure above 160 mmHg or diastolic blood pressure above 100mmHg. Patients with severe hepatic failure or renal failure or cardiac disorder and identified inappropriate patients for this study by the physicians in charge. Patients with proliferative retinopathy (excluding old proliferative retinopathy without necessary of intervention) and patients with maculopathy with necessary of intervention. Patients who have history of malignancy Excluding following patients Patients who have history of cured basal cell tumor by appropriate treatment or uterocervical carcinoma in situ Patients who have history of malignancy more than 1 year before and also have no reappearance Patients who onset malignancy during the period of the study. Patients with severe complication and identified inappropriate patients for this study by the physicians in charge. The pregnant women or women having possibilities of being pregnant and the women with breast-feeding Other patients who are identified inappropriate patients for this study by the physicians in charge.
Investigators
Similar Trials
Active, not recruiting
Phase 1
GLP-1 and hyperoxia for organ protection in heart surgeryWe investigate the efficacy of commercially available GLP-1 analog for reducing organ damage in patients undergoing heart surgery (i.e. coronary artery bypass grafting and/or aortic valve replacement).In addition we investigate the efficacy of restrictive versus liberal oxygenation (i.e. FiO2 50% versus FiO2 100%) for reducing organ damage during weaning after heart surgery. The study is a two-by-two factorial designed randomized clinical trial.MedDRA version: 20.0Level: LLTClassification code 10008937Term: Chronic ischemic heart disease, unspecifiedSystem Organ Class: 100000011627EUCTR2015-003050-41-DKRigshospitalet
Completed
Not Applicable
GLP-1 analogue therapy on glycemic control in patients undergoing cardiac surgerytype2 diabetesJPRN-UMIN000008003GLOLIA investigation group70
Completed
Not Applicable
The efficacy of GLP-1 receptor agonist on glycemic control in type 2 diabetes with inadequate DPP-4 inhibitor therapy.type 2 diabetesJPRN-UMIN000006959Department of Metabolism and Endocrinology, Juntendo Graduate University of Medicine90
Completed
Not Applicable
ong-term efficacy and safety of the GLP-1 receptor agonist liraglutide in Japanese patients with type 2 diabetes mellitus.Type 2 Diabetes mellitusJPRN-UMIN000037603akakinen clinic1,000
Recruiting
Not Applicable
Observation of using GLP-1 receptor agonist for wellness of brain activity in type 2 diabetes patients with mild cognitive impairmentJPRN-UMIN000030840Ogawa Red Cross Hospital50